FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 

For period ending September 03, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 

1.  Identity of the i ssuer or  the underlying issuer of existing shares to which voting rights are attached:	GlaxoSmithKline Plc
2. Reason for notification  (yes/no)
An acquisition or disposal of voting rights		Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):______________
3. Full name of person (s)  subject to the notification obligation:	Legal & General Group Plc (Group) Legal & General Investment Management Limited (LGIM)
4. Full name of shareholder (s)   (if different from 3.):	Legal & General Assurance (Pensions Management) Limited (PMC) Legal & General Group Plc ( L&G )
5. Date  of the transaction  (and date on which the threshold is crossed or reached if different):	01  September 2008
6. Date on which issuer notified:	03 September 2008
7. Threshold(s) that  is/are  crossed or reached:	Below  5% (Group) Below  5% (LGIM)

8. Notified details:

A:  Voting rights attached to shares
Class/type of shares    if possible using the ISIN CODE	Situation previous to the  Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
				Direct	Indirect	Direct	Indirect
ORD GBP 0.25	261,984,775	261,984,775	Below 5%

B:  Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date	Exercise/   Conversion Period/ Date	Number of voting rights  that may be acquired if the instrument is exercised/ converted.	% of voting rights

Total (A+B)
Number of voting rights	% of voting rights
Below 5%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Proxy Voting:
10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:	Notification using  the total voting rights  figure of  5, 237,361,030
14. Contact name:	Helen Lewis  (LGIM)
15. Contact telephone number:	020 3124 3851

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: September 03, 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc